BioDrugs Clinical Immunotherapeutics, Biopharmaceuticals and Gene Therapy Introduction BioDrugs is a journal that healthcare decision makers can turn to for succinct and comprehensive coverage of current and future biotechnology drugs and immunomodulatory agents, as well as the current and future implications of genomics and gene therapy. Aims and Scope BioDrugs provides healthcare decision makers with a regular programme of peer reviewed articles covering issues in the clinical application of biotechnological and immunological knowledge to the treatment of human disease. Definitive reviews on a broad range of topics in biopharmaceuticals, gene therapy and clinical immunology, including the development and optimum therapeutic use of agents based on biotechnological and immunological principles and the treatment of disorders with an immunological component Disease management reviews including recommendations for specific clinical situations Adis Drug Evaluations reviewing the properties and place in therapy of both newer and established drugs Adis New Drug Profiles with expert commentary Original research articles on the human clinical pharmacology, clinical development and therapeutic optimisation of relevant drugs will also be considered for publication.
All manuscripts are subject to peer review by international experts.
Letters to the Editor are welcomed and will be considered for publication. A free sample issue of this journal is available either online or a free print copy may be requested . In addition to an Editorial Board comprised of internationally acknowledged experts in their fields, the Journal has an extensive peer-review panel, ensuring that all manuscripts meet the high standards expected of BioDrugs . An acknowledgement of this panel can be found in the December issue of the Journal. Instructions for Authors Articles in BioDrugs are either commissioned from leading international experts, or are prepared by Adis International scientific editors.